At-Home Biomarkers Test Kits

Clean the Sky - Positive Eco Trends & Breakthroughs

Noom's New Kit Lets Members See How Habits are Shaping Their Health

— May 27, 2026 — Lifestyle
Noom announced the launch of its at-home Biomarkers Test Kit to members in the United States so that they can get fast, reliable insights on everything from cardiovascular, metabolic, hormonal, and inflammatory health. With this kit, Noom members can collect a small blood sample in less than 10 minutes with the Tasso+ device, skip the trip to the lab, and get clinically meaningful results within about a week. And at a later point in time, users can take the test again and take note of the changes that are measurably making a difference.

Noom’s kit includes testing of 17 clinically significant biomarker-based insights, and there's value for GLP-1 members, who can monitor their blood sugar and other key benefits.

Trend Themes

  1. At-home Biomarker Testing — Wider adoption of fingerstick or Tasso+-style kits is enabling clinically meaningful lab results outside traditional facilities, creating room for decentralized diagnostics to reshape patient monitoring.
  2. Behavior-linked Health Insights — Connecting longitudinal biomarker data with habit and lifestyle logs is producing more granular correlations between daily behaviors and measurable physiological change, highlighting opportunities for evidence-driven habit interventions.
  3. Subscription Health Analytics — Regular, repeatable testing tied to membership models is generating continuous datasets that support predictive analytics and personalized risk stratification over time.

Industry Implications

  1. Digital Health Platforms — Platforms that combine coaching with biometric feedback are positioned to offer differentiated, outcome-focused services as users demand quantifiable proof of behavior change.
  2. Diagnostics and Lab Services — Lab providers and diagnostics firms face pressure to evolve from centralized testing to hybrid home-to-lab workflows that preserve clinical rigor while improving convenience.
  3. Pharmaceutical and Therapeutics — Drug developers, especially those in metabolic and GLP-1 therapies, are gaining access to near real-time biomarkers that can inform adherence, response heterogeneity, and post-market evidence generation.
7.1
Score
Popularity
Activity
Freshness